Feedback
Settings

Settings

Goto Application

289,715 results
Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C12Q

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 28,972
1.WO/2024/083867BIOMARKER
WO - 25.04.2024
Int.Class A61K 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
 Appl.No PCT/EP2023/078887 Applicant ULTIMOVACS ASA Inventor ELLINGSEN, Espen Basmo
A method for identifying a subject to whom a combination therapy is to be administered, wherein the subject is a cancer patient. The combination therapy comprises administration of: (I) a PD-1/PD-L1 immune checkpoint inhibitor and/or a CTLA-4 immune checkpoint inhibitor, with (II) a polypeptide comprising a region of at least 12 amino acids of a tumor-associated antigen. The method comprises: (a) evaluating a level of one or more of (i) to (iv) in a biological sample obtained from a cancer patient: (i) tumor mutational burden; (ii) PD-L1 expression; (iii) a tumor infiltrating lymphocyte; and/or (iv) neoantigens, wherein the level of one or more of (i) to (iv) is determined to be low; and (b) identifying the cancer patient who provided the biological sample as a subject to whom the combination therapy is to be administered.
2.WO/2024/083612PREDICTION OF AN OUTCOME OF NEOADJUVANT ANDROGEN DEPRIVATION THERAPY IN A PROSTATE CANCER SUBJECT
WO - 25.04.2024
Int.Class C12Q 1/6886
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
6886for cancer
 Appl.No PCT/EP2023/078212 Applicant KONINKLIJKE PHILIPS N.V. Inventor HOFFMANN, Ralf Dieter
The invention relates to a method of predicting a response of a prostate cancer subject to neoadjuvant androgen deprivation therapy. The method is based on predicting an outcome based on the expression levels of genes identified herein. The invention provides a method to establish whether neoadjuvant androgen deprivation therapy is useful for a subject and thus should be administered or not. Further provided are the use of a kit for determining expression levels for predicting a response of a prostate cancer subject to neoadjuvant androgen deprivation therapy.
3.WO/2024/084197METHODS FOR REDUCING THE LEVEL OF XENOBIOTICS IN AN ENVIRONMENT
WO - 25.04.2024
Int.Class A61K 35/74
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
74Bacteria
 Appl.No PCT/GB2023/052687 Applicant CAMBRIDGE ENTERPRISE LIMITED Inventor PATIL, Kiran Raosaheb
The invention relates to methods for reducing the level of xenobiotic in an environment by contacting the environment with a composition comprising one or more bacterial strains. The invention also relates to bacterial strains for use in method of reducing the level of xenobiotic in a subject. The invention also relates to compositions comprising one or more bacterial strains.
4.WO/2024/082681TRUNCATED RESPIRATORY SYNCYTIAL VIRUS F PROTEIN AND USE THEREOF
WO - 25.04.2024
Int.Class C07K 19/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
19Hybrid peptides
 Appl.No PCT/CN2023/102342 Applicant XIAMEN UNIVERSITY Inventor ZHENG, Zizheng
Provided are a fusion protein, and a nucleic acid molecule comprising a nucleotide sequence encoding the fusion protein. The present invention also relates to a vaccine comprising the fusion protein or the nucleic acid molecule. Furthermore, the present invention also relates to a method for preventing and/or treating RSV infections or diseases and/or symptoms caused by RSV infections by means of using the fusion protein, the nucleic acid molecule and the vaccine.
5.WO/2024/084421TREATMENT OF VASCULAR DISEASES ASSOCIATED WITH GENETIC VARIATIONS IN ACTA2
WO - 25.04.2024
Int.Class A61P 9/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9Drugs for disorders of the cardiovascular system
 Appl.No PCT/IB2023/060542 Applicant QRGENETICS LTD. Inventor WALD-ALTMAN, Shane
The present invention provides methods of treatment, diagnostics, kits, and formulations for treating a subject having one or more genetic variations in an Actin alpha 2 (ACTA2) gene involving administering a therapeutically effective amount of a pterin of Formula I such as sapropterin to a subject, contingent upon a presence of one or more genetic variations in Actin alpha 2 (ACTA2) gene.
6.WO/2024/084211ANALYSIS OF A POLYMER
WO - 25.04.2024
Int.Class G01N 33/487
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
483Physical analysis of biological material
487of liquid biological material
 Appl.No PCT/GB2023/052708 Applicant OXFORD NANOPORE TECHNOLOGIES PLC Inventor HALL, Graham James
A nanopore device and a method of controlling a nanopore device for analysing a polymer, the nanopore device comprising at least one sensor element, the sensor element comprising a nanopore and a sensor, the method comprising: translocating a polymer through the nanopore; generating a series of measurements using the sensor as the polymer translocates through the nanopore; comparing the series of measurements to a reference data to determine a measurement of similarity; operating the nanopore device to eject the polymer from the nanopore if the measure of similarity is determined to be below a threshold value; and determining whether the polymer has been successfully ejected from the nanopore by analysing a further set of measurements taken by the sensor.
7.WO/2024/083866CANCER TREATMENT
WO - 25.04.2024
Int.Class A61K 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
 Appl.No PCT/EP2023/078886 Applicant ULTIMOVACS ASA Inventor ELLINGSEN, Espen Basmo
A polypeptide, a nucleic acid molecule, a T-cell receptor or a T-cell displaying the T-cell receptor for use in the prevention or treatment of mesothelioma in a subject is provided. A polypeptide, a nucleic acid, a T-cell receptor or a T-cell displaying the T-cell receptor for use in the prevention or treatment of an epithelioid cancer in a subject is also provided. The polypeptide comprises a region of at least 12 amino acids of a tumour- associated antigen or a sequence having at least 80% identity to the region. The nucleic acid molecule comprises a nucleotide encoding the polypeptide. The T-cell receptor is specific for the polypeptide. The polypeptide, nucleic acid molecule, T-cell receptor or T- cell is administered simultaneously, separately or sequentially with an immune checkpoint inhibitor.
8.WO/2024/085141FLUID DEVICE, AND METHOD FOR DETECTING TARGET MOLECULE
WO - 25.04.2024
Int.Class G01N 33/53
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
 Appl.No PCT/JP2023/037512 Applicant TOPPAN HOLDINGS INC. Inventor HORIUCHI Yosuke
This fluid device comprises a base plate and a wall material provided on the base plate, and includes a plurality of first wells surrounded by the base plate and the wall material, and a plurality of second wells provided respectively in bottom portions of the first wells, the bottom portions being an upper surface of the base plate.
9.WO/2024/085246KIT AND METHOD FOR DETERMINING PRESENCE OR ABSENCE OF AFFECTION OF DEMENTIA
WO - 25.04.2024
Int.Class C12N 15/09
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
 Appl.No PCT/JP2023/038014 Applicant KANEKA CORPORATION Inventor TAGUCHI Akihiko
The purpose of the present invention is to provide: a biomarker which can determine the presence or absence of the affection of dementia with high sensitivity and specificity by means of a simple operation; and a method, a kit, and a device which are for the determination.　Provided is a method for determining the presence or absence of the affection or onset risk of dementia in a subject, the method comprising a step for calculating the ratio of the expression level of connexin 43 genes and/or the expression level of prolyl hydroxylase domain protein 3 genes and the expression level of connexin 37 genes.
10.WO/2024/086776HYBRID MICROBEAD ARRAYS
WO - 25.04.2024
Int.Class G01N 21/25
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
21Investigating or analysing materials by the use of optical means, i.e. using infra-red, visible or ultra-violet light
17Systems in which incident light is modified in accordance with the properties of the material investigated
25Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
 Appl.No PCT/US2023/077391 Applicant 10X GENOMICS, INC. Inventor XING, Siyuan
The present disclosure relates generally to arrays for transcriptomics assays and methods of preparing the same. The disclosure provides arrays having features on a substrate and filling material in the spaces on the substrate that are not occupied by the features. Particularly, the disclosure provides arrays in which the features have a first refractive index at a wavelength and the filling material have a second refractive index at the same wavelength, such that the difference between the first refractive index and the second refractive index is no greater than about 10%. The disclosure also provides methods of preparing such arrays as well as methods of detecting biological analytes using said arrays.
# -